Aldafermin
As of the edition of 20 October 2026, Aldafermin is a protein: stopped in 2025; acts on FGF1, FGFR4 and KLB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Protein
- Registered trials
- 14, 1 stopped early
- Disease areas
- Digestive system; Hormones; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 9 | 9 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| NGM Biopharmaceuticals | Lead sponsor of trials | 2013 to now |